Is Levalbuterol tartrate HFA inhalation the same as Anoro Ellipta?

No. Levalbuterol tartrate HFA inhalation (LEVALBUTEROL TARTRATE) and Anoro Ellipta (UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, LEVALBUTEROL TARTRATE or UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from LEVALBUTEROL TARTRATE to UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

LEVALBUTEROL TARTRATE vs UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

Compare LEVALBUTEROL TARTRATE (Levalbuterol tartrate HFA inhalation) and UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE (Anoro Ellipta) — clinical data, side effects, and patient experiences.

LEVALBUTEROL TARTRATE

Levalbuterol tartrate HFA inhalation · Beta-2 Agonist Bronchodilator

How it works

12.1 Mechanism of Action Activation of beta 2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular con...

Approved for

See full prescribing information

OralTablet

UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

Anoro Ellipta · Beta-2 Agonist Bronchodilator

How it works

12.1 Mechanism of Action ANORO ELLIPTA ANORO ELLIPTA contains both umeclidinium and vilanterol. The mechanisms of action described below for the individual components apply to ANOR...

Approved for

an anticholinergic

and vilanterol

a long-acting beta 2 -adrenergic agonist (LABA)

5.2 )

Respiratory (inhalation)Tablet

Quick Comparison

LEVALBUTEROL TARTRATEUMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

Drug Class

Beta-2 Agonist Bronchodilator

Route

Oral

Respiratory (inhalation)

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

LEVALBUTEROL TARTRATE

Shortness of Breath

>10%

Fatigue

1-10%

Cough

1-10%

Drug Not Working

1-10%

Nausea

1-10%

Headache

1-10%

Diarrhea

0.1-1%

Dizziness

0.1-1%

UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

Shortness of Breath

>10%

Drug Not Working

>10%

Cough

1-10%

Fatigue

0.1-1%

Headache

0.1-1%

Condition Worsened

0.1-1%

FDA Warnings

LEVALBUTEROL TARTRATE

No specific warnings

UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

5 WARNINGS AND PRECAUTIONS • LABA monotherapy (without an inhaled corticosteroid) for asthma increases the risk of serious asthma-related events
2 ) • Do not use in combination with additional therapy containing a LABA because of risk of overdose
1 Serious Asthma-Related Events – Hospitalizations, Intubations, Death The safety and effectiveness of ANORO ELLIPTA in patients with asthma have not been established
Use of LABA as monotherapy (without ICS) for asthma is associated with an increased risk of asthma-related death

Clinical Trial Data

No head-to-head clinical studies found for LEVALBUTEROL TARTRATE vs UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE.

LEVALBUTEROL TARTRATE vs UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE: What You Should Know

Key Differences

Both LEVALBUTEROL TARTRATE and UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE belong to the Beta-2 Agonist Bronchodilator class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. LEVALBUTEROL TARTRATE is administered via Oral, whereas UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE uses Respiratory (inhalation). Route of administration can affect onset of action and patient adherence.

Safety Considerations

UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

FORMOTEROL FUMARATE vs UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE→FORMOTEROL FUMARATE vs LEVALBUTEROL TARTRATE→ALBUTEROL vs UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE→ALBUTEROL vs LEVALBUTEROL TARTRATE→LEVALBUTEROL HYDROCHLORIDE vs UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE→LEVALBUTEROL HYDROCHLORIDE vs LEVALBUTEROL TARTRATE→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

LEVALBUTEROL TARTRATE: DailyMed label · FAERS adverse events · ClinicalTrials.gov
UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

LEVALBUTEROL TARTRATE vs UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

Compare LEVALBUTEROL TARTRATE (Levalbuterol tartrate HFA inhalation) and UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE (Anoro Ellipta) — clinical data, side effects, and patient experiences.

LEVALBUTEROL TARTRATE

Levalbuterol tartrate HFA inhalation · Beta-2 Agonist Bronchodilator

How it works

12.1 Mechanism of Action Activation of beta 2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular con...

Approved for

See full prescribing information

OralTablet

UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

Anoro Ellipta · Beta-2 Agonist Bronchodilator

How it works

12.1 Mechanism of Action ANORO ELLIPTA ANORO ELLIPTA contains both umeclidinium and vilanterol. The mechanisms of action described below for the individual components apply to ANOR...

Approved for

an anticholinergic

and vilanterol

a long-acting beta 2 -adrenergic agonist (LABA)

5.2 )

Respiratory (inhalation)Tablet

Quick Comparison

LEVALBUTEROL TARTRATEUMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

Drug Class

Beta-2 Agonist Bronchodilator

Route

Oral

Respiratory (inhalation)

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

LEVALBUTEROL TARTRATE

Shortness of Breath

>10%

Fatigue

1-10%

Cough

1-10%

Drug Not Working

1-10%

Nausea

1-10%

Headache

1-10%

Diarrhea

0.1-1%

Dizziness

0.1-1%

UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

Shortness of Breath

>10%

Drug Not Working

>10%

Cough

1-10%

Fatigue

0.1-1%

Headache

0.1-1%

Condition Worsened

0.1-1%

FDA Warnings

LEVALBUTEROL TARTRATE

No specific warnings

UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

5 WARNINGS AND PRECAUTIONS • LABA monotherapy (without an inhaled corticosteroid) for asthma increases the risk of serious asthma-related events
2 ) • Do not use in combination with additional therapy containing a LABA because of risk of overdose
1 Serious Asthma-Related Events – Hospitalizations, Intubations, Death The safety and effectiveness of ANORO ELLIPTA in patients with asthma have not been established
Use of LABA as monotherapy (without ICS) for asthma is associated with an increased risk of asthma-related death

Clinical Trial Data

No head-to-head clinical studies found for LEVALBUTEROL TARTRATE vs UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE.

LEVALBUTEROL TARTRATE vs UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

LEVALBUTEROL TARTRATE: DailyMed label · FAERS adverse events · ClinicalTrials.gov
UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE: DailyMed label · FAERS adverse events · ClinicalTrials.gov